Patient characteristics
| Patient . | Diagnosis . | Age, y . | Sex, P/D . | CMV serostatus, P/D . | Disease status at SCT . | DFS, d . | DLI days after SCT . | Relapse . | aGVHD, day, grade (site) . | WT1 expression before SCT, WT1/ABL . | Maximal WT1 CD8+ T-cell response after SCT, % (time after SCT) . | ALC D30 . | T-cell chimerism D30 . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | B-ALL | 20 | M/M | +/+ | CR2 | 780 | 60 | N | 47, II (S,G) | 0.0028 | 0.57 (30 d) | 3295 | 100 |
| 2 | Ph+ B-ALL | 33 | F/F | +/+ | CR2 | 120 | 45 | Y | 82, II (S) | 0.0107 | 0.12 (60 d) | 458 | 97 |
| 3 | B-ALL | 27 | F/F | +/+ | Primary refractory | 75 | 45 | Y | 48, II (S) | 0.1882 | 0.63 (60 d) | 926 | 100 |
| 4 | B-ALL | 33 | F/M | +/+ | CR2 | 339 | 45 | Y | 34, II (S) | 0.0024 | 0.12 (30 d) | 755 | 97 |
| 5 | B-ALL | 15 | M/M | +/+ | Primary refractory | 154 | 60 | Y | N | 0.0015 | 0.13 (14 mo) | 612 | 99 |
| 6 | B-ALL | 28 | F/F | +/+ | CR2 | 97 | N | N | 33, IV (S, G) | 0.0007 | 0 | 1792 | 100 |
| 7 | B-ALL | 37 | M/F | +/+ | CR3 | 374 | N | N | 38, II (S) | 0.0031 | 0 | 1320 | 100 |
| 8 | B-ALL | 10 | F/F | +/+ | CR2 | 2809 | 58 | N | 88–100, II (G) | 0 | 0 | 54 | N/A |
| 9 | B-ALL | 22 | F/F | +/+ | CR2 | 1508 | 38 | N | 46–80, II (S,G) | 0 | 0 | 34 | N/A |
| 10 | B-ALL | 36 | F/F | +/+ | Primary refractory | 192 | N | N | 32, II (S,G) | 0 | 0 | 1156 | 98 |
| Patient . | Diagnosis . | Age, y . | Sex, P/D . | CMV serostatus, P/D . | Disease status at SCT . | DFS, d . | DLI days after SCT . | Relapse . | aGVHD, day, grade (site) . | WT1 expression before SCT, WT1/ABL . | Maximal WT1 CD8+ T-cell response after SCT, % (time after SCT) . | ALC D30 . | T-cell chimerism D30 . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | B-ALL | 20 | M/M | +/+ | CR2 | 780 | 60 | N | 47, II (S,G) | 0.0028 | 0.57 (30 d) | 3295 | 100 |
| 2 | Ph+ B-ALL | 33 | F/F | +/+ | CR2 | 120 | 45 | Y | 82, II (S) | 0.0107 | 0.12 (60 d) | 458 | 97 |
| 3 | B-ALL | 27 | F/F | +/+ | Primary refractory | 75 | 45 | Y | 48, II (S) | 0.1882 | 0.63 (60 d) | 926 | 100 |
| 4 | B-ALL | 33 | F/M | +/+ | CR2 | 339 | 45 | Y | 34, II (S) | 0.0024 | 0.12 (30 d) | 755 | 97 |
| 5 | B-ALL | 15 | M/M | +/+ | Primary refractory | 154 | 60 | Y | N | 0.0015 | 0.13 (14 mo) | 612 | 99 |
| 6 | B-ALL | 28 | F/F | +/+ | CR2 | 97 | N | N | 33, IV (S, G) | 0.0007 | 0 | 1792 | 100 |
| 7 | B-ALL | 37 | M/F | +/+ | CR3 | 374 | N | N | 38, II (S) | 0.0031 | 0 | 1320 | 100 |
| 8 | B-ALL | 10 | F/F | +/+ | CR2 | 2809 | 58 | N | 88–100, II (G) | 0 | 0 | 54 | N/A |
| 9 | B-ALL | 22 | F/F | +/+ | CR2 | 1508 | 38 | N | 46–80, II (S,G) | 0 | 0 | 34 | N/A |
| 10 | B-ALL | 36 | F/F | +/+ | Primary refractory | 192 | N | N | 32, II (S,G) | 0 | 0 | 1156 | 98 |
ALC indicates absolute lymphocyte count (× 103/mL); aGVHD, acute graft-versus-host disease; CR, complete remission; D, donor; DFS, disease-free survival; F, female; G, gut; M, male; N/A, not applicable; N, no; Ph, Philadelphia; P, patient; S, skin; and Y, yes.